1. Home
  2. CGEN vs MRCC Comparison

CGEN vs MRCC Comparison

Compare CGEN & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.48

Market Cap

143.1M

Sector

Health Care

ML Signal

HOLD

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

HOLD

Current Price

$6.26

Market Cap

133.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEN
MRCC
Founded
1993
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
143.1M
133.2M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
CGEN
MRCC
Price
$1.48
$6.26
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
405.6K
132.1K
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
11.71%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,903,000.00
$43,742,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$231.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.13
$5.86
52 Week High
$2.66
$8.85

Technical Indicators

Market Signals
Indicator
CGEN
MRCC
Relative Strength Index (RSI) 40.30 41.65
Support Level $1.47 $5.99
Resistance Level $1.55 $6.80
Average True Range (ATR) 0.07 0.19
MACD -0.00 -0.03
Stochastic Oscillator 16.98 33.13

Price Performance

Historical Comparison
CGEN
MRCC

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

Share on Social Networks: